2001/75/EC: Commission Decision of 18 January 2001 for safety and potency testing of foot-and-mouth disease vaccines and bluetongue vaccines (notified under document number C(2001) 118)

• Articles: 4

Article 1

1. The Community shall make arrangements for appropriate safety and potency testing of:

- foot-and-mouth disease virus antigens purchased in 1993 and since then kept as a part of the EU emergency stock,

- foot-and-mouth disease vaccine produced in Turkey and used in a prophylactic vaccination programme which includes vaccination of susceptible animals kept in the area of Turkish Thrace,

- bluetongue vaccines produced outside the European Community and purchased for an emergency stock.

2. The maximum cost of the measures referred to in paragraph 1 shall be up to EUR 430000.

Article 2

The measures mentioned in Article 1 shall be carried out by the Commission in cooperation with the supplier designated by call for tender.

Article 3

1. To meet the objectives of Articles 1 and 2 the Commission shall conclude contracts without delay.

2. The Director-General of the Directorate-General for Health and Consumer Protection shall be authorised to sign the contracts on behalf of the European Commission.

Article 4

This Decision is addressed to the Member States.

Done at Brussels, 18 January 2001.

For the Commission

David Byrne

Member of the Commission

(1) OJ L 224, 18.8.1990, p. 19.

(2) OJ L 160, 26.6.1999, p. 103.

(3) OJ L 368, 31.12.1991, p. 21.

(4) OJ L 301, 24.11.1999, p. 6.

(5) OJ L 280, 13.11.1993, p. 33.

(6) OJ L 269, 11.11.1995, p. 29.

(7) OJ L 16, 21.1.1998, p. 45.

(8) OJ L 95, 15.4.2000, p. 39.